EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-SA 4.0

Neurosteroids and premenstrual dysphoric disorder

Marie Bixo iD, Louise Stiernman, Torbjörn Bäckström

The British Journal of Psychiatry · 2026-07 · 229 (1) · 92-100

DOI: 10.1192/bjp.2025.103 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The British Journal of Psychiatry, online erschienen am 16.06.2025. Verfasst von Marie Bixo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Obstetrics and Gynaecology, Umeå University, Sweden. Hauptthemen laut MEDLINE: Premenstrual Dysphoric Disorder, Neurosteroids, Pregnanolone, Receptors, GABA-A. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Premenstrual dysphoric disorder (PMDD) is common, with at least 3% of the female population affected by one or more of the typical mood symptoms of depression, irritability, mood swings and anxiety. The cyclicity and close relationship to the luteal phase of the menstrual cycle is characteristic for this syndrome and positive allosteric modulators (PAMs) on the GABA A receptor, especially allopregnanolone, are believed to be involved in the symptomatology.

Aim

To summarise the research on the role of PAMs and other neuroactive steroids in the pathophysiology of PMDD.

Method

PubMed was searched for articles including the terms Premenstrual syndrome, AND neurosteroids OR allopregnanolone OR GABA OR oestradiol. Many additional publications were previously known to the authors and basic animal research was covered in a secondary step through reference lists.

Results

There is evidence that allopregnanolone, like other PAMs of the GABA A receptor, is sedative in high concentrations and, in a minor proportion of the population, causes anxiety and irritability at lower levels, pointing to an inter-individual difference in sensitivity. In research comparing women with PMDD and healthy controls, differences in brain function and subcomposition of GABA A receptors related to levels of allopregnanolone have been found. Also, the varying levels of neuroactive steroids in general seem to worsen the symptoms. Supressed ovulation is effective but add-back hormones are necessary to prevent severe side-effects and could cause adverse mood in these individuals.

Conclusions

There is yet no effective treatment for PMDD available. Allopregnanolone seems to be a key provocateur of PMDD symptoms in susceptible individuals. Future research should focus on interventions that interfere with the effects of neurosteroids or the plasticity of the GABA A receptor itself.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Premenstrual Dysphoric DisorderNeurosteroidsPregnanoloneReceptors, GABA-AHumansFemale

Stichwörter der Autor:innen

Neurosteroidsallopregnanolonepremenstrual dysphoric disorderγ-amino-butyric acid (GABA)

Substanzen

NeurosteroidsPregnanoloneReceptors, GABA-A

Autor:innen und Institutionen

  • Department of Clinical Sciences, Obstetrics and Gynaecology, Umeå University, Sweden.

ORCID-Profile: Marie Bixo

Zitieren

APA

Bixo, M., Stiernman, L., & Bäckström, T. (2026). Neurosteroids and premenstrual dysphoric disorder. The British Journal of Psychiatry, 229(1), 92-100. https://doi.org/10.1192/bjp.2025.103

Vancouver

Bixo M, Stiernman L, Bäckström T. Neurosteroids and premenstrual dysphoric disorder. The British Journal of Psychiatry. 2026;229(1):92-100. doi:10.1192/bjp.2025.103

BibTeX
@article{Bixo2026,
  author = {Bixo, Marie and Stiernman, Louise and Bäckström, Torbjörn},
  title = {Neurosteroids and premenstrual dysphoric disorder},
  journal = {The British Journal of Psychiatry},
  year = {2026},
  volume = {229},
  number = {1},
  pages = {92--100},
  doi = {10.1192/bjp.2025.103}
}
Kostenlos starten →